Regulatory FDA Approves First New Molecular Entity Under National Priority Voucher Program FDAThe U.S.RegulatoryRead full story pharminent April 1, 2026 (Last updated: April 1, 2026) FDA The U.S. RegulatoryRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Ambrosia adds a megaround for obesity drugsNext: Eli Lilly’s Oral Obesity Pill Approved, Kicking Off Renewed Novo Rivalry Related Stories Regulatory Outlook Therapeutics Secures FDA Approval for LYTENAVA pharminent July 31, 2026 Regulatory Outlook finally claims FDA approval for AMD drug pharminent July 27, 2026 Regulatory Outlook Therapeutics wins FDA approval for Lytenava in wet AMD pharminent July 27, 2026
